28 November 2024 - Ghent ICC
Explore the exciting career paths at innovative biotech firms. During this session speakers of various (young) companies will take the stage to tell more about the diverse roles available at their companies. This session is perfect for anyone interested in pursuing or growing a career in this fast-paced, transformative field or for those who are interested in getting to know these companies.
Dr. Liesbeth Ceelen is a leader with extensive experience in multinational environments as well as in start-up and scale-up companies. Over the last 15 years, she has gained expertise in operational and quality management, sales, scientific business development and strategic growth across the biotech and healthcare fields. As CEO of BioLizard, Liesbeth steers the BioLizard team, bringing both the scientific background and profound management skills to make BioLizard the go-to data science consultancy company across Europe and the US. Liesbeth leads by example, and her driving ambition is to inspire people and to help them grow. She does this not only within her role as CEO, but also through her involvement in Women on Board and the TOPX Network for Women in Life Sciences, and her mentorship via A Seat at the Table and Flanders.bio. Liesbeth’s work has been widely lauded: she was named named one of the Top 50 Inspiring Belgian Women in Tech in 2022 and one of the 10 Most Disruptive Women Leaders to Watch in 2023, alongside BioLizard being recognised as a finalist for the 2023 Healthtech company of the Year at the 2023 European Lifestars Awards. Alongside this, Liesbeth has recently finished an executive MBA programme at the Vlerick business school - embodying her focus on continuous learning and growth. Last but not least, Liesbeth is the proud mum of Lore, Elise and Lukas.
About BioLizard
BioLizard, located in Ghent, leverages its expertise in bioinformatics, biostatistics, machine learning, artificial intelligence and data mining to solve the most challenging questions in biology and deliver solutions to clients. By combining expertise from diverse backgrounds, BioLizard provides a complete solution to its client - from data analysis to the system integration and the development of an AI-aided interpretation system. The company was founded by Novalis Biotech Incubation. For more information visit the website.
Dieter Defever | Employee Communications and engagement Manager | argenx
Dieter Defever is an experienced scientist and seasoned communicator whose journey at argenx exemplifies his commitment to the company’s culture and his ability to drive positive change. Dieter graduated in 2001 with a Bachelor’s degree in Biomedical and Pharmaceutical Sciences from Ghent University of Applied Sciences. His academic journey continued with a focus on virology at the Veterinarian School’s Virology Lab from 2002 to 2004. Dieter then embarked on a long and impactful career at VIB, contributing to the Molecular Cancer Biology Lab and, later, the Cytokine Receptor Lab from 2004 to 2020.
In 2020, Dieter joined argenx as a Bioanalytical Scientist. Over the next four years, he played a crucial role in the Bioanalysis team as a bioanalytical Study Monitor, leveraging his extensive scientific knowledge and expertise to advance the company’s research and development efforts.
In addition to his scientific work, Dieter is passionate about argenx’s people and has played a key role in advancing conversations around the company’s culture. He became increasingly involved in fostering a dynamic and inspiring work environment across the organization, ensuring that all Argonauts benefit from a cohesive and innovative company culture.
Dieter’s enthusiasm for this strategic engagement work enabled his recent transition to a new role as an Employee Communications and Engagement Manager within the company’s Communications and Investor Relations team. In his new position, Dieter is responsible for enhancing employee communications and engagement, managing argenx’s Ghent campus, and leading initiatives to bring the company’s Cultural Pillars and Operating Principles to life, further solidifying argenx’s mission and values. Dieter’s advancement at argenx is also a testament to the effectiveness of the company’s Professional Development Plan (PDP) process, which ensures alignment between an employee’s strengths and their professional growth.
About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker in the U.S., Japan, Israel, the EU, the UK, China and Canada. The company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Twitter, and Instagram.
For job seekers | For employers | Join BCF Career Event |
| Register BCF ONLINE | |
Powered by: Hyphen Projects Privacy Policy Terms & Conditions Chamber of Commerce: 32110979 |
© Copyright 2024 by Hyphen Projects